Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corabotase - Ipsen

Next Previous
Drug Profile

Corabotase - Ipsen

Alternative Names: Botulinum toxin A longer acting - Ipsen; IPN-10200; Long acting toxin - Ipsen; Longer-acting neurotoxin - Ipsen; modified recombinant Botulinum Neurotoxin/A; mrBoNT/A; mrBoNT/AB; RNI™

Latest Information Update: 26 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Antispastics; Anxiolytics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Gastrokinetics; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glabellar lines
  • Phase II Migraine; Torticollis
  • Phase I/II Muscle spasticity

Most Recent Events

  • 21 Aug 2026 Ipsen plans the phase III LAURITE 3 trial for Glabellar lines in China (IM, Injection), in October 2026 (NCT07779252)
  • 16 May 2026 Updated efficacy and adverse events data from the phase Ib/II LANTIC trial in Glabellar lines released by Ipsen
  • 25 Feb 2026 Ipsen plans a phase III trial for Glabellar lines (Mid-stage disease) in February 2026 (IM, Injection) (NCT07427797)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top